Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

The role of kinetic context in apparent biased agonism at GPCRs.

Klein Herenbrink C, Sykes DA, Donthamsetti P, Canals M, Coudrat T, Shonberg J, Scammells PJ, Capuano B, Sexton PM, Charlton SJ, Javitch JA, Christopoulos A, Lane JR.

Nat Commun. 2016 Feb 24;7:10842. doi: 10.1038/ncomms10842.

2.

Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.

Szabo M, Klein Herenbrink C, Christopoulos A, Lane JR, Capuano B.

J Med Chem. 2014 Jun 12;57(11):4924-39. doi: 10.1021/jm500457x. Epub 2014 May 30.

PMID:
24827597
3.

A structure-activity analysis of biased agonism at the dopamine D2 receptor.

Shonberg J, Herenbrink CK, López L, Christopoulos A, Scammells PJ, Capuano B, Lane JR.

J Med Chem. 2013 Nov 27;56(22):9199-221. doi: 10.1021/jm401318w. Epub 2013 Nov 8.

PMID:
24138311
4.

Increasing the density of the D2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazole.

Koener B, Focant MC, Bosier B, Maloteaux JM, Hermans E.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan 10;36(1):60-70. doi: 10.1016/j.pnpbp.2011.08.007. Epub 2011 Aug 17.

PMID:
21871520
5.

Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor.

Thompson GL, Lane JR, Coudrat T, Sexton PM, Christopoulos A, Canals M.

Biochem Pharmacol. 2016 Aug 1;113:70-87. doi: 10.1016/j.bcp.2016.05.014. Epub 2016 Jun 7.

PMID:
27286929
6.

In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.

Jordan S, Regardie K, Johnson JL, Chen R, Kambayashi J, McQuade R, Kitagawa H, Tadori Y, Kikuchi T.

J Psychopharmacol. 2007 Aug;21(6):620-7. Epub 2006 Nov 8.

PMID:
17092971
7.

Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor.

Tschammer N, Bollinger S, Kenakin T, Gmeiner P.

Mol Pharmacol. 2011 Mar;79(3):575-85. doi: 10.1124/mol.110.068106. Epub 2010 Dec 16.

PMID:
21163968
8.

Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics.

Kara E, Lin H, Strange PG.

J Neurochem. 2010 Mar;112(6):1442-53. doi: 10.1111/j.1471-4159.2009.06554.x. Epub 2009 Dec 24.

9.

Constitutive coupling of a chimeric dopamine D2/alpha 1B receptor to the phospholipase C pathway: inverse agonism to silent antagonism by neuroleptic drugs.

Wurch T, Boutet-Robinet EA, Palmier C, Colpaert FC, Pauwels PJ.

J Pharmacol Exp Ther. 2003 Jan;304(1):380-90.

PMID:
12490615
10.

Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.

Chen X, Sassano MF, Zheng L, Setola V, Chen M, Bai X, Frye SV, Wetsel WC, Roth BL, Jin J.

J Med Chem. 2012 Aug 23;55(16):7141-53. doi: 10.1021/jm300603y. Epub 2012 Aug 13.

11.

Biased Agonism of Endogenous Opioid Peptides at the μ-Opioid Receptor.

Thompson GL, Lane JR, Coudrat T, Sexton PM, Christopoulos A, Canals M.

Mol Pharmacol. 2015 Aug;88(2):335-46. doi: 10.1124/mol.115.098848. Epub 2015 May 26.

PMID:
26013541
12.

A kinetic view of GPCR allostery and biased agonism.

Lane JR, May LT, Parton RG, Sexton PM, Christopoulos A.

Nat Chem Biol. 2017 Aug 18;13(9):929-937. doi: 10.1038/nchembio.2431.

PMID:
28820879
13.

Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.

Heinrich JN, Brennan J, Lai MH, Sullivan K, Hornby G, Popiolek M, Jiang LX, Pausch MH, Stack G, Marquis KL, Andree TH.

Eur J Pharmacol. 2006 Dec 15;552(1-3):36-45. Epub 2006 Sep 14.

PMID:
17056032
14.

Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET.

Shalgunov V, van Wieringen JP, Janssen HM, Fransen PM, Dierckx RA, Michel MC, Booij J, Elsinga PH.

J Nucl Med. 2015 Jan;56(1):133-9. doi: 10.2967/jnumed.114.145466. Epub 2014 Dec 4.

15.

Partial agonism and fast dissociation of LASSBio-579 at dopamine D2 receptor.

Pompeu TE, Monteiro do Monte F, Bosier B, Fraga CA, Barreiro EJ, Menegatti R, Hermans E, Noël F.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Oct 1;62:1-6. doi: 10.1016/j.pnpbp.2015.04.003. Epub 2015 Apr 17.

16.

Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways.

Brust TF, Hayes MP, Roman DL, Burris KD, Watts VJ.

J Pharmacol Exp Ther. 2015 Mar;352(3):480-93. doi: 10.1124/jpet.114.220293. Epub 2014 Dec 24.

17.

Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.

Shonberg J, Lopez L, Scammells PJ, Christopoulos A, Capuano B, Lane JR.

Med Res Rev. 2014 Nov;34(6):1286-330. doi: 10.1002/med.21318. Epub 2014 May 5. Review.

PMID:
24796277
18.

In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.

Tadori Y, Forbes RA, McQuade RD, Kikuchi T.

Eur J Pharmacol. 2011 Oct 15;668(3):355-65. doi: 10.1016/j.ejphar.2011.07.020. Epub 2011 Jul 29.

PMID:
21816144
19.

Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like effects in rats.

Jantschak F, Brosda J, Franke RT, Fink H, Möller D, Hübner H, Gmeiner P, Pertz HH.

J Pharmacol Exp Ther. 2013 Oct;347(1):57-68. doi: 10.1124/jpet.113.205997. Epub 2013 Jul 17.

PMID:
23863695
20.

Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.

Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval M, Leduc N, Newman-Tancredi A.

Eur J Pharmacol. 2006 Mar 27;535(1-3):135-44. Epub 2006 Mar 22.

PMID:
16554049

Supplemental Content

Support Center